|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
GENE THERAPY
From the Clinical Gene Therapy Branch, National Human
Genome Research Institute, National Institutes of Health, Bethesda, MD.
Resting lymphocytes are refractory to gene transfer using Moloney
murine leukemia virus (MMLV)-based retroviral vectors because of their
quiescent status. Recently, it has been shown that lentiviral vectors
are capable of transferring genes into nondividing and terminally
differentiated cells. We used human immunodeficiency virus type-1
(HIV-1)-based vectors expressing enhanced green fluorescent protein
(EGFP) driven by different promoters (CMV, MPSV, or PGK) and
investigated their ability to transduce human T- and B-cell lines, as well as resting or activated primary peripheral and umbilical
cord blood lymphocytes. The effects of the presence or the absence of
HIV-1 accessory proteins (Vif, Vpr, Vpu, and Nef) in the vector system
were also assessed. Flow cytometry analysis showed no differences in
the ability of these vectors of transferring the reporter gene into
lymphocytic lines and mitogen-stimulated primary lymphocytes in the
presence or the absence of HIV-1 accessory proteins (APs). Similarly,
viral supernatants generated in the presence of accessory genes could
efficiently transduce various subsets of resting lymphocytes and
provide long-term expression of the transgene. No significant
transduction-induced changes in cell activation or cycling status were
observed and Alu-HIV-1 long terminal repeat polymerase chain reaction
(LTR PCR) analysis demonstrated integration of the vector sequences at
the molecular level. In contrast, in the absence of HIV-1 APs,
lentiviral vectors failed to integrate and express the transgene in
resting lymphocytes. These results show that transduction of primary
resting lymphocytes with HIV-1-based vectors requires the presence of
viral accessory proteins.
(Blood. 2000;96:1309-1316) Genetic alteration of peripheral blood T
lymphocytes has been shown to have potential therapeutic applications
for inherited and acquired immunodeficiencies.1-3 Similar
strategies have also been proposed to deliver immunomodulatory
cytokines for cancer therapy.4 Although Moloney murine
leukemia virus (MMLV)-based retroviral vectors have been used
successfully to transduce cells from various tissues, including cells
of hematopoietic origin, transduction of primary lymphocytes has been
limited primarily by the requirement that the cells be proliferating
for stable retroviral integration. Potent induction of cell
proliferation in vitro has been used to overcome this
problem.1,5 In vitro culture, however, is known to alter
the CD4+/CD8+ ratios and T-cell
receptor (TCR) repertoire composition of T lymphocytes and may
induce changes of their cytokine secretion profile.1,6,7
Therefore, to preserve the functional integrity of the target
lymphocytes, it would be desirable to avoid inducing cell division
during the gene transfer procedures.
As an alternative approach to retroviral-mediated gene transfer, we
explored the use of human immunodeficiency virus type-1 (HIV-1)-based
lentiviral vectors. These vectors are attractive in that either
proliferating or quiescent cells can be transduced and the sustained
expression of the transgene can be achieved by the stable integration
of vector into the host cell genome.8-11 These important
advantages of lentiviral vectors derive from partial retention of
wild-type HIV-1 biologic characteristics. However, whether HIV-1 is
able to establish stable infection in primary quiescent lymphocytes
remains controversial. Several in vitro reports have demonstrated that
HIV-1 can readily enter quiescent T cells in culture and subsequently
be induced to replicate after stimulation through antigenic or
costimulatory processes.12,13 On the other hand, some
investigators have shown that HIV-1 infection of quiescent T cells in
vitro results in only partially reverse transcribed viral DNA that is
labile and rapidly degraded,14,15 whereas others have
reported the establishment of a complete infectious cycle with
detectable production of early mRNA transcription.12 In
support of these last findings, Ostrowski et al16 have
recently demonstrated the presence of integrated HIV-1 provirus within naïve CD45RA+/CD62L+/CD4+ T
cells isolated from patients who are infected with HIV-1. In addition,
replication-competent HIV-1 was isolated from the same cells after in
vitro stimulation, suggesting that naïve CD4+ T
cells may be a reservoir for HIV-1. Similarly, Zhang et
al17 have also recently shown productive infection and
replication of SIV and HIV in resting T cells in rhesus monkeys and
HIV-1-infected human subjects, respectively. Taken together, these
studies suggest that, after HIV-1 entry, additional host factors must
be provided concomitant with T-cell activation to permit productive
replication and integration of HIV-1 DNA into the host
genome.13,18 Part of the explanation for this complex
virus-host interaction probably lies in the organization of the
HIV-1 viral genome that encodes 6 regulatory proteins that are not
found in other classes of retroviruses. Some of these products (Tat and
Rev) are essential for HIV replication, whereas others (Vif, Vpr,
Vpu, and Nef) appear to modulate the infection and replication
processes in some nondividing cell types and have therefore been
associated with HIV-1 virulence.19,20
Although wild-type HIV-1 infection of resting or activated primary
lymphocytes has been studied extensively, the ability of replication-defective HIV-1-based gene transfer vectors to infecting these cell types has not been studied in detail. In this study, we have
attempted to elucidate the importance of viral accessory proteins in
HIV-1-based vector-mediated gene transfer into lymphocytic cells. As
targets, we used immortalized T- and B-lymphoid cell lines, as well as
well-characterized, highly purified resting and mitogen-stimulated
human lymphocytes obtained from adult peripheral blood and umbilical
cord blood samples. We have also examined the relative efficiencies of
different promoters in driving long-term transgene expression in these
cell types.
Plasmid construction
Cell culture
Vector production and transductions Replication-defective lentiviral particles pseudotyped with VSV-G envelope were produced by 3-plasmid transient transfection of 293T cells as previously described8 with 15 µg of one of the gene transfer constructs (pHR'CMV-EGFP, pHR'PGK-EGFP, or pHR'MPSV-EGFP), 10 µg of either pCMV R8.2 or pCMVR8.91, and 5 µg of pMD.G, using a calcium phosphate transfection kit (Gibco-BRL).
The transfection medium was replaced after 12 hours with fresh culture
medium. Viral supernatants were harvested at 65 hours after
transfection and filtered through 0.45 µm filters (Nalgene,
Rochester, NY). Supernatants were either used immediately for
transductions or were aliquoted and stored frozen at  80°C until
use. Titers of viral supernatants were determined by quantification of
p24 gag by enzyme-linked immunosorbent assay (ELISA)
(Coulter Diagnostics, Hialeah, FL), and also by transducing 293T cells
with serial dilutions of viral supernatants, followed by flow cytometry
analysis of EGFP-positive cells, 48 hours after transduction. It was
assumed that 1 ng of p24 is approximately equivalent to 1000 to 5000 transducing units.23 All lentiviral vector preparations
were tested for the presence of replication-competent lentivirus (RCL)
by transducing 293T cells and assaying culture medium for the presence
of p24 gag after at least 5 cell passages. No RCL was
detectable in any of the vector preparations tested.
Transductions of lymphoid cells were performed on fibronectin-coated 6-well plates (Becton Dickinson, San Jose, CA) in the presence of 5 µg/mL polybrene (Sigma Chemical Co), at an multiplicity of infection (MOI) of approximately 5 to 10. Cells were exposed to viral supernatant at a density of 106 cells per well in 3 mL final volume. After 30 minutes of centrifugation at 800g at 32°C, transductions were allowed to proceed for additional 48 hours. After transduction, cells were washed 3 times with phosphate-buffered saline (PBS), trypsinized for 5 minutes to remove potential unadsorbed viral particles, and reincubated in fresh culture medium. In the case of resting lymphocytes, after transduction, cells were cultured either in the absence of stimulation for 10 days or stimulated with PHA (5 µg/mL) and rhIL-2 (100 U/mL) for 3 days, then cultured in the presence of rhIL-2 (100 U/mL) and stimulated with PHA every 2 weeks. Cell samples were harvested periodically for flow cytometry analysis of EGFP expression. Flow cytometry To assess the purity and activation status of the target lymphocyte population, 5 × 105 adherent cells-depleted, resting or mitogen-stimulated lymphocytes were stained with fluorescein isothiocyanate (FITC)- and/or phycoerythrin (PE)-conjugated monoclonal antibodies (mAbs) (all from Becton Dickinson) for the lineage specific human markers CD3, CD4, CD8, CD19, CD13, CD14, and CD56, and the cell activation markers CD69, CD25, and CD71. Cells transduced under different conditions were stained with mAbs to the same cell surface markers on day 5 after transduction. Isotype FITC- and/or PE-conjugated control antibodies were used to assess specificity of immunostaining procedures and to set quadrant regions. After staining and washing, cells were fixed in 4% paraformaldehyde and 5000 to 10 000 events were acquired with a FACSCalibur and analyzed using the CellQuest software (Becton Dickinson).Cell cycle analysis Cell cycle status was monitored by measuring cellular DNA content using propidium iodide (PI) staining and flow cytometry analysis.24 Briefly, cell samples were obtained before and after transduction, washed in PBS, and resuspended in ice cold 80% ethanol. After additional washes with PBS, cells were treated with 1 mL of PBS containing 180 units of RNase A at 37°C for 30 minutes and subsequently stained with PBS containing 30 µg/mL of PI (Sigma Chemical). The cellular DNA content was then analyzed using a FACSCalibur. Data acquisition and analysis were performed with the CellQuest and ModFit LT softwares, respectively.Assays for integrated HIV-1 vector in primary human lymphocytes To demonstrate the integration of the HIV-1 vector in the transduced lymphocytes, genomic DNA was purified from both activated and resting primary lymphocytes 5 days after transduction and subjected to Alu-HIV-1 LTR PCR as described previously.25 Briefly, the first PCR was carried out using a sense oligomer specific for the conserved sequences of human Alu (5'-GGCACTTTGGGAGGCCAAGG-3') and an antisense oligomer specific for the long terminal sequences (LTR) of HIV-1 (5'-TTTTCGCGAGCGGCCGCTGCTAGAGATTTTCCACACTG-3'). In all amplifications, 50 µL of reaction mixture containing 250 ng of genomic DNA, 10 mmol/L Tris-HCl, 50 mmol/L KCl, 0.2 mmol/L dNTPs, 1.5 mmol/L MgCl2, 25 pmol of each of the primers, and 2 units of platinum Taq DNA polymerase (Gibco-BRL) were used. After the first DNA denaturation and activation of the enzyme at 94°C for 3 minutes, 35 amplification cycles were performed consisting of denaturation for 1 minute at 94°C, annealing for 1 minute at 60°C, and extension for 2.5 minutes at 72°C. One aliquot (one-fiftieth) of the first PCR products was subjected to a second PCR amplification using the previously published nested primers, NI-2 5' (5'-CACACACAAGGCTACTTCCCT-3') and NI-2 3' (5'-GCCACTCCCCAGTCCCGCCC-3'), resulting in the amplification of a 317-base pair (bp) portion of the HIV-1 LTR region. Twenty-nine amplification cycles were performed (30 seconds at 95°C, 30 seconds at 63°C, and 1 minute at 72°C) in a 50-µL PCR containing 10 mmol/L Tris-HCl, 50 mmol/L KCl, 0.2 mmol/L dNTPs, 1.25 mmol/L MgCl2, 25 pmol of each of the nested primers, and 2 units of Gold Taq DNA polymerase (Gibco-BRL). In control reactions, genomic DNA that had not been subjected to the first round of PCR was also amplified using the second PCR primers to exclude the presence of plasmid and/or residual nonintegrated vector DNA. PCR products were analyzed by gel electrophoresis, followed by Southern blot and hybridization by using 32P end-labeled oligonucleotide probes (5'-GGATGGTGCTTCAAGTTAGTACC-3'). To further confirm the specificity of the amplification product, direct automated sequencing of the PCR fragment was performed using the dideoxynucleotide method and the NI-2 5' and NI-2 3' primers.
Multiply attenuated HIV-1 vectors efficiently transduce and stably express the transgene in lymphoid cell lines To investigate the role of HIV-1 accessory proteins (APs) in lentiviral-mediated gene transfer into actively proliferating transformed lymphoid cell lines, VSV-G pseudotyped lentiviral supernatants were generated using 2 different packaging constructs, pCMVR8.2 (providing expression of all APs)9 and
pCMVR8.91 (lacking all accessory genes),22 and
different gene transfer vectors carrying EGFP under the transcriptional
control of 3 different promoters (Figure
1A). Consistent with earlier
reports,8,22 pseudotyping of the pHR'-based vector
was highly efficient, even in the absence of accessory genes, with
titers of the unconcentrated virus measured on 293T cells reaching 5 to
10 × 106 transducing units per milliliter. We
used FACS analysis to test in parallel the transduction
efficiency of these vectors on rapidly proliferating T-cell lines,
SupT1 and Jurkat, as well as EBV-lymphoblastoid B cells. The
stability of reporter gene expression in the transduced cells was
followed for at least 6 months after transduction in in vitro culture.
As shown in Table 1, lentiviral particles
generated using the pCMVR8.91 packaging construct transduced
lymphoid cell lines as efficiently as virus stocks that had been
prepared using the pCMVR8.2 construct. EGFP expression was very
stable, as determined by the high percentage (more than or equal to
70%) of cells showing sustained expression of EGFP for 4 months after
transduction (Figure 1B) regardless of the promoters used (CMV, PGK, or
MPSV). Taken together, these results indicate that APs are
dispensable for transduction of actively proliferating T- and
B-cell lines, and that all 3 promoters studied were similarly active in
these cells.
Transduction of mitogen-stimulated primary lymphocytes does not require the presence of accessory proteins To determine the relative efficiency of the HIV-1-vector pseudotypes to infect and stably express the transgene in mitogen-activated primary human lymphocytes in the presence or absence of APs, lymphocytes were prepared from 5 different PB and 2 CB samples obtained from healthy donors and stimulated with PHA and rhIL-2 for 3 days. Immunophenotyping and FACS analysis data were obtained from 3 PB samples and showed that 95.7% ± 3.8% (mean ± SE) of the cells were CD3+ of which 65.0% ± 2.9% and 35.0% ± 2.9% were CD4+ and CD8+ cells, respectively. The majority of cells were positive for the expression of cellular activation markers CD25 (96.8% ± 1.4%) and CD71 (89.0% ± 1.7%). Cell cycle analysis by PI staining showed that 30.0% ± 0.9% of the cells was in S-phase, demonstrating active proliferation, as expected. These cells were exposed to pHR'PGK-EGFP lentiviral vector produced in the presence or the absence of APs and analyzed for EGFP expression by FACS 3 days after transduction and periodically thereafter for up to 4 months. Similarly to the lymphoid cell lines, we observed no differences between the promoters CMV, PGK, and MPSV in driving long-term transgene expression in activated primary lymphocytes (Figure 1B). On average, the percentage of EGFP-positive cells at 3 days after transduction was more than 90%, regardless of the presence or the absence of APs in the vector preparation (Table 2). The average number of EGFP-positive cells decreased to approximately 70% during the following 2 weeks in culture (Table 2 and Figure 1B) and gradually declined to approximately 25% at 4 months after transduction. Similar results were obtained with activated CBLs transduced with the same vectors (Table 2).
We next assessed the ability of the same vectors to transduce different
subsets of mitogen-stimulated lymphocytes. Representative results with
activated PBLs transduced with pHR'PGK-EGFP vectors are shown in Figure
2. Analysis of EGFP expression 5 days
after transduction consistently demonstrated more than or equal to 60% gene transfer efficiency in activated CD3+ lymphocytes,
the majority of which were also highly positive for activation markers
CD25. Interestingly, the number of EGFP-positive CD8+
lymphocytes was reduced when cells were transduced by vectors lacking
APs, whereas no clear differences were noted for CD4+
cells. Similar results were observed in a second independent experiment
with cells from different donors (data not shown). These results show
that, with the possible exception of CD8+ T cells, vector
stocks produced using packaging constructs devoid of APs encoding
regions were as efficient as the corresponding stocks containing APs in
transducing activated lymphocytes.
HIV-1 accessory proteins are required for lentiviral-mediated gene transfer into resting primary lymphocytes Purified lymphocytes were prepared from 5 PB samples and 2 CB samples from different healthy donors. The immunophenotypes of unstimulated, adherent cells-depleted PBLs were assessed by immunostaining of 3 PB samples for the cell surface markers CD3, CD4, CD8, CD19, CD56, CD13, and CD14. The resting status of isolated cells was determined by analyzing the expression of different cell surface activation markers (CD69, CD25, and CD71), and by PI staining. After 2 successive depletion steps by plastic adherence, the primary lymphocyte fraction (more than 99% purity) contained approximately 90.0% ± 1.7% CD3+ cells (which included 59.0% ± 4.9% CD4+ and 28.3% ± 4.9% CD8+ cells), 2.4% ± 0.5% CD56+ natural killer (NK) cells, and 10.0% ± 3.3% CD19+ B cells. Only very small numbers (less than 1%) of cells expressing the CD13 and/or CD14 monocyte/macrophage specific molecules could be detected. Although very few cells showed weak staining for some cell activation markers CD69 (1.8% ± 0.6%), CD25 (2.9% ± 0.9%), and CD71 (3.0% ± 1.0%), cell cycle analysis by PI staining showed that the majority of the cells (98.8% ± 0.4%) were in the G0/G1 phase. In all our experiments, the unstimulated cells could be maintained in a stable resting state (G0/G1, activation marker mostly negative) during cell culture for up to 10 days.Unstimulated cells were transduced with VSV-G pseudotyped vector particles generated in the presence or the absence of APs. The results presented in Table 2 show that G0/G1 lymphocytes were successfully transduced with pHR'PGK-EGFP vector stocks carrying all APs. The mean percentage of EGFP-expressing cells 3 days after transduction (90.2% ± 1.1%) was comparable to that observed in mitogen-activated lymphocytes transduced with similar vector preparation. Further, stable expression of EGFP was observed for up to 4 months in culture, in a considerable fraction of the cells that were stimulated with PHA and rhIL-2 after transduction (Table 2). In contrast, vector stocks assembled from APs negative packaging construct did not efficiently transduce resting lymphocytes as shown by the extremely low percentage of EGFP positive cells (4.8% ± 0.7%) at 3 days after transduction. In addition, no significant change in EGFP expression could be observed with time after stimulation with PHA and rhIL-2 (Table 2). These results indicate that effective transduction of unstimulated lymphocytes requires lentiviral vector preparations produced in the presence of APs. Similar results were obtained using the pHR'CMV-EGFP vector (data not shown). Cells kept in culture without mitogen stimulation for 10 days after HIV-1-vector transduction showed approximately 65% of EGFP positive cells if transduced with APs containing vectors, but only approximately 2% if APs negative vectors were used. Finally, we examined the efficiency of these vectors in transducing and
expressing EGFP in different subsets of unstimulated, resting
lymphocytes. The results of a representative experiment with PBLs
transduced with pHR'PGK-EGFP vectors and analyzed at 5 days after
transduction are presented in Figure 3.
CD4+ and CD8+ subsets of T cells,
CD56+ NK cells, as well as CD19+ B cells, could
be successfully transduced using vector pseudotypes containing APs,
whereas the vector lacking APs failed to transduce these cells. To
further define whether the transduction procedure-induced cellular
activation was responsible for effective gene transfer, combined
analysis of EGFP expression and cell surface activation markers by
immunostaining or cell cycle analysis by PI staining was performed in
transduced resting lymphocytes at 5 days after transduction. The
results presented in Figure 4A indicate
that a high-level expression of EGFP could be detected in majority of
the cells, which were negative for the expression of activation markers, CD69, CD25, or CD71. Although a small increase (2%-4%) was
observed in the number of cells expressing CD69, CD25, and CD71 among
the transduced populations, irrespective of the vectors used (Figure
4A), no significant differences in their cell cycle status could be
detected (Figure 4B). These data suggest that the transduction
procedure itself did not induce significant amount of cellular
activation signals that could account for the successful transduction
of resting lymphocytes by the lentiviral vector carrying APs.
Detection of integrated HIV-1 vector DNA in primary human lymphocytes transduced with HIV-1 vectors Although long-term EGFP expression is most likely attributable to vector integration, the transgene expression observed at 5 days after transduction could be due to pseudotransduction. To demonstrate vector integration at this early time points, genomic DNA extracted from transduced lymphocytes was analyzed using a previously described Alu-HIV-1 LTR PCR detection method.25 Alu regions are repetitive sequences scattered throughout the human genomic DNA and it is therefore likely that an integrated HIV-1 vector sequence would lie in the proximity of one such a region. Primers designed in the human Alu and HIV-1 LTR sequences allow amplification of the junctional fragments overlapping the integration of the HIV-1 vector in the host genomic DNA. As HIV-1 vectors can integrate in different sites within the same cell and among different cells, these PCR products are expected to have variable sizes and therefore to generate a "diffused" (smeared) signal after Southern blot and probing for HIV-1 LTR specific sequences. The second round of PCR using nested primers within the HIV-1 LTR results in the generation of a unique amplification product only from cells containing the Alu-HIV-1 LTR junctional fragment, which can be easily detected by Southern blotting. As shown in Figure 5, the expression of EGFP correlated with a detectable Alu-HIV-1 LTR PCR products, thus supporting the conclusion that EGFP expression detectable in transduced lymphocytes was the result of vector integration. In contrast, no PCR product could be detected in resting lymphocytes transduced with HIV-1 vectors devoid of APs, indicating that in the absence of APs no vector integration had taken place in these cells.
Introduction of genes into primary resting lymphocytes may have applications in clinical gene therapy approaches where it is not desirable to induce cell proliferation. In contrast to onco-retroviruses that have provided the basis for most gene transfer vectors currently used for clinical applications, HIV-1 has the capacity to infect nondividing cells. However, differences exist in the relative ability of gene transfer vectors based on HIV-1 to integrate into the host DNA of different types of nondividing cells. In particular, some of the HIV-1 accessory genes appear to be required for efficient lentiviral vector-mediated gene transfer into specific tissues, as it is the case of hepatocytes where Vif and Vpr seem to be necessary.26 The molecular details of the HIV-1 infection of primary resting lymphocytes is now fairly well understood; however, little is known about the requirements for efficient transduction of these cells by HIV-1-based recombinant vector pseudotypes. Recently, Unutmaz et al27 have reported that an HIV-1 vector system pseudotyped with VSV-G similar to the APs defective pseudotypes described here, failed to transduce resting lymphocytes without cytokine prestimulation.27 Our results demonstrate that replication-defective, VSV-G pseudotyped HIV-1 vectors could efficiently transfer and stably express the EGFP transgene in lymphoid cell lines and various subsets of mitogen-stimulated and resting primary human lymphocytes. By comparing the ability of vectors produced in the presence or the absence of the 4 accessory genes, we found no significant differences in their ability to transduce T and B lymphoblastoid cells or actively proliferating primary lymphocytes. However, when the same vector preparations were used to transduce resting lymphocytes (residing in G0/G1 phase of cell cycle and negative for activation markers), striking differences were observed. In line with the results of Unutmaz et al,27 our data demonstrate that lentiviral vectors generated in the absence of APs were severely impaired in their ability to transduce these cells and that stimulation with PHA plus rhIL-2 after transduction did not increase the gene transfer efficiency (Table 2 and Figure 3). Interestingly, however, viral supernatants packaged in the presence of all APs could efficiently transduce resting T, NK, and B cells. EGFP expression was observed in significant proportions of cells up to 10 days after transduction in the absence of stimulation, and up to 4 months when the same cells were maintained in culture by periodical stimulation with PHA and rhIL-2. In addition to long-term expression, nested Alu-HIV-1 LTR PCR analysis of integrated HIV-1 proviral DNA indicated that the transgene expression observed in primary lympohocytes (both mitogen-stimulated and resting) was derived from the integrated vector sequences (Figure 5). We also observed a gradual decrease in the percentage of EGFP positive cells in the primary lymphocyte population over the course of several weeks of in vitro culture, from approximately 90% to 20%. This finding can be attributed to selective survival of a subset of lymphocytes or to extinction of viral gene expression. In vivo experiments in immunodeficient mice may help address this issue. Experimental conditions were designed to ensure that our model was representative of the quiescent status of lymphocytes in vivo. To eliminate in vitro variables known to contribute to cell activation, a negative selection by stringent adherent cell depletion rather than a positive selection was used for lymphocyte isolation and low FBS concentration (1%) was used to supplement the culture medium. Under these conditions, more than 98% of the recovered cells were found in G0/G1 phase of the cell cycle. To monitor whether the transduction procedure itself induced metabolic activation, expression of cell activation antigens and changes in cycle status by PI staining were analyzed in 2 different experiments after exposure to lentiviral vector supernatants. No significant changes in the levels of expression were observed for CD69, CD25, and CD71 activation molecules in the target population, and only 1% to 2% of G0/G1 cells moved into the S phase during transduction. To the best of our analytical abilities therefore, the lymphocyte population used in this study is comparable to the quiescent lymphocytes found in the peripheral circulation in vivo. In our hands, HIV-1 vector-mediated gene transfer and stable
integration into resting lymphocytes, irrespective of their source, peripheral blood (adult) or umbilical cord blood (neonatal), did not
require activation-induced cell proliferation, but was rather dependent
on lentiviral vector preparations produced in the presence of HIV-1
APs. Taking into account our results and data from the literature, we
envisage the following explanations for the apparent need for APs for
efficient lentiviral-mediated transduction of resting lymphocytes; (a)
the APs could induce early cell activation signals for example,
phosphorylation of p62/NAK kinase,28
NF- Although HIV-1-based vectors are likely to behave differently from
wild-type virus, some explanation for our findings may come from the
knowledge of the roles played by different APs in the HIV-1 replicative
cycle. It is now believed that several viral proteins, including p17
matrix, RT, Vpr, and Nef, are important to the establishment
of HIV-1 infection in nondividing cells.18,31-34 Considerable evidence is also available to suggest that Vif is likely
to play an essential role during infection in vivo 34-37 and in vitro in the case of primary PBLs and some lymphoid cell lines.38 Further, it has been proposed that Vif might be
essential for the stability of proviral DNA
complex.34,39,40 In addition, Vpr has been implicated in
nuclear localization of viral nucleic acids in nondividing cells and
its absence could affect nuclear import of the HIV-1 preintegration
complex.41 Information is also beginning to emerge on the
third early protein, Nef, which is expressed at a much higher level
than other proteins in infected cells. In a variety of experimental
studies, Nef was shown to down-regulate MHC class I molecule
expression,39,42 enhance viral
infectivity,43-46 and modulate cellular activation and
signal transduction pathways, most probably through association with cellular signaling molecules.20,30,47 More importantly,
Swingler et al48 have shown that resting T cells, which
are normally refractory to productive infection, became activated and
permissive to HIV-1 infection when exposed to supernatants from
macrophages that were engineered to express Nef by adenoviral-mediated
gene transfer. This effect was found to be mediated through chemokines (MIP1 In addition to these virus-derived gene products, other cellular molecules expressed by the virus-producing 293T cells in concomitance with or in response to the viral accessory gene product(s) may be important players. It has been reported that HIV-1 can incorporate a wide array of cell membrane molecules while budding from the infected cells.49-53 Of particular interest is the demonstration that increased incorporation of HLA-DR and ICAM molecules in HIV-1 virions resulted in enhanced viral infectivity on CD4 negative cell lines.50 In their recent work, Haase and coworkers17 suggested that interaction between resting T cells and major histocompatibility complex molecules may allow a low level of stimulation without the apparent commitment of the cells to full activation and progression through the cell cycle, but with alteration of the status of the cells to an extent sufficient to support HIV-1 infection and propagation. In this regard, it is possible to speculate that 293T cell-derived molecules may associate with pseudotyped lentiviral vectors and play a role in the transduction process. In conclusion, our studies indicate that the multiply attenuated, VSV-G pseudotyped HIV-1-based vectors are highly efficient in transducing actively proliferating primary lymphocytes and established lymphoid cell lines. We have provided evidence, however, that the presence of HIV-1 APs is important for the establishment of stable transduction in quiescent lymphocytes. These findings may lead to additional insights into the mechanism whereby the HIV APs regulate T-cell activity and contribute to the pathogenesis of HIV infection. HIV-1 vectors are currently being engineered to reduce the complement of genes needed for transduction of various cell types. As APs are associated with HIV-1 virulence, safe and efficient vector systems should exclude any nonessential viral proteins that may cause undesirable effects in the context of clinical applications. Dissection of the importance and role of the various APs by using different packaging constructs devoid of individual accessory genes22 and elucidation of their potential cellular partners that allow transduction of resting lymphocytes therefore warrant further investigation that will lead to the development of safe and efficient lentivirus-based vectors for clinical gene transfer applications.
Submitted January 24, 2000; accepted April 7, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Fabio Candotti, Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda MD 20892-1851; e-mail: fabio{at}nhgri.nih.gov.
1.
Blaese RM, Culver KW, Miller AD, et al.
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
Science.
1995;270:475-480
2.
Bordignon C, Notarangelo LD, Nobili N, et al.
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.
Science.
1995;270:470-475 3. Chinen J, Aguilar-Cordova E, Ng-Tang D, et al. Protection of primary human T cells from HIV infection by Trev: a transdominant fusion gene. Hum Gene Ther. 1997;8:861-868[Medline] [Order article via Infotrieve].
4.
Treisman J, Hwu P, Minamoto S, et al.
Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen.
Blood.
1995;85:139-145
5.
Mavilio F, Ferrari G, Rossini S, et al.
Peripheral blood lymphocytes as target cells of retroviral vector- mediated gene transfer.
Blood.
1994;83:1988-1997
6.
Dietrich PY, Walker PR, Schnuriger V, et al.
TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture.
Int Immunol.
1997;9:1073-1083 7. Seder RA. Acquisition of lymphokine-producing phenotype by CD4+ T cells. J Allergy Clin Immunol. 1994;94:1195-1202[Medline] [Order article via Infotrieve]. 8. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267[Abstract].
9.
Naldini L, Blomer U, Gage FH, et al.
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.
Proc Natl Acad Sci U S A.
1996;93:11382-11388
10.
Reiser J, Harmison G, Kluepfel-Stahl S, et al.
Transduction of nondividing cells using pseudotyped defective high- titer HIV type 1 particles.
Proc Natl Acad Sci U S A.
1996;93:15266-15271
11.
Miyoshi H, Takahashi M, Gage FH, et al.
Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.
Proc Natl Acad Sci U S A.
1997;94:10319-10323 12. Stevenson M, Stanwick TL, Dempsey MP, et al. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 1990;9:1551-1560[Medline] [Order article via Infotrieve]. 13. Spina CA, Guatelli JC, Richman DD. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol. 1995;69:2977-2988[Abstract].
14.
Zagury D, Bernard J, Leonard R, et al.
Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS.
Science.
1986;231:850-853 15. Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990;61:213-222[Medline] [Order article via Infotrieve].
16.
Ostrowski MA, Chun TW, Justement SJ, et al.
Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals.
J Virol.
1999;73:6430-6435
17.
Zhang Z, Schuler T, Zupancic M, et al.
Sexual transmission and propagation of SIV and HIV in resting and activated CD4(+) T cells.
Science.
1999;286:1353-1357
18.
von Schwedler U, Kornbluth RS, Trono D.
The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes.
Proc Natl Acad Sci U S A.
1994;91:6992-6996
19.
Emerman M, Malim MH.
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology.
Science.
1998;280:1880-1884 20. Cullen BR. HIV-1 auxiliary proteins: making connections in a dying cell. Cell. 1998;93:685-692[Medline] [Order article via Infotrieve].
21.
Halene S, Wang L, Cooper RM, et al.
Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector.
Blood.
1999;94:3349-3357 22. Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997;15:871-875[Medline] [Order article via Infotrieve].
23.
Zufferey R, Dull T, Mandel RJ, et al.
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.
J Virol.
1998;72:9873-9880 24. Telford WG, King LE, Fraker PJ. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry. 1992;13:137-143[Medline] [Order article via Infotrieve].
25.
Chun TW, Stuyver L, Mizell SB, et al.
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.
Proc Natl Acad Sci U S A.
1997;94:13193-13197 26. Kafri T, Blomer U, Peterson DA, et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet. 1997;17:314-317[Medline] [Order article via Infotrieve].
27.
Unutmaz D, KewalRamani VN, Marmon S, et al.
Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.
J Exp Med.
1999;189:1735-1746
28.
Xu XN, Laffert B, Screaton GR, et al.
Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain.
J Exp Med.
1999;189:1489-1496 29. Baur AS, Sawai ET, Dazin P, et al. HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity. 1994;1:373-384[Medline] [Order article via Infotrieve]. 30. Fackler OT, Luo W, Geyer M, et al. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol Cell. 1999;3:729-739[Medline] [Order article via Infotrieve].
31.
Simon JH, Malim MH.
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes.
J Virol.
1996;70:5297-5305 32. Trono D. HIV accessory proteins: leading roles for the supporting cast. Cell. 1995;82:189-192[Medline] [Order article via Infotrieve]. 33. Volsky DJ, Potash MJ, Simm M, et al. The human immunodeficiency virus type 1 vif gene: the road from an accessory to an essential role in human immunodeficiency virus type 1 replication. Curr Top Microbiol Immunol. 1995;193:157-168[Medline] [Order article via Infotrieve].
34.
von Schwedler U, Song J, Aiken C, et al.
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.
J Virol.
1993;67:4945-4955 35. Akari H, Sakuragi J, Takebe Y, et al. Biological characterization of human immunodeficiency virus type 1 and type 2 mutants in human peripheral blood mononuclear cells. Arch Virol. 1992;123:157-167[Medline] [Order article via Infotrieve].
36.
Fisher AG, Ensoli B, Ivanoff L, et al.
The sor gene of HIV-1 is required for efficient virus transmission in vitro.
Science.
1987;237:888-893
37.
Luciw PA, Cheng-Mayer C, Levy JA.
Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication.
Proc Natl Acad Sci U S A.
1987;84:1434-1438
38.
Gabuzda DH, Lawrence K, Langhoff E, et al.
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.
J Virol.
1992;66:6489-6495 39. Collins KL, Chen BK, Kalams SA, et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 1998;391:397-401[Medline] [Order article via Infotrieve]. 40. Courcoul M, Patience C, Rey F, et al. Peripheral blood mononuclear cells produce normal amounts of defective Vif-human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol. 1995;69:2068-2074[Abstract].
41.
Heinzinger NK, Bukinsky MI, Haggerty SA, et al.
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
Proc Natl Acad Sci U S A.
1994;91:7311-7315 42. Schwartz O, Marechal V, Le Gall S, et al. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med. 1996;2:338-342[Medline] [Order article via Infotrieve]. 43. Aiken C, Trono D. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol. 1995;69:5048-5056[Abstract]. 44. Wiskerchen M, Cheng-Mayer C. HIV-1 Nef association with cellular serine kinase correlates with enhanced virion infectivity and efficient proviral DNA synthesis. Virology. 1996;224:292-301[Medline] [Order article via Infotrieve]. 45. Sawai ET, Khan IH, Montbriand PM, et al. Activation of PAK by HIV and SIV Nef: importance for AIDS in rhesus macaques. Curr Biol. 1996;6:1519-1527[Medline] [Order article via Infotrieve]. 46. Saksela K, Cheng G, Baltimore D. Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. EMBO J. 1995;14:484-491[Medline] [Order article via Infotrieve]. 47. Stevenson M. Pathway to understanding AIDS. Nat Struct Biol. 1996;3:303-306[Medline] [Order article via Infotrieve]. 48. Swingler S, Mann A, Jacque J, et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med. 1999;5:997-103[Medline] [Order article via Infotrieve]. 49. Cantin R, Fortin JF, Tremblay M. The amount of host HLA-DR proteins acquired by HIV-1 is virus strain- and cell type-specific. Virology. 1996;218:372-381[Medline] [Order article via Infotrieve]. 50. Castilletti C, Capobianchi MR, Fais S, et al. HIV type 1 grown on interferon gamma-treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA- DR and enhanced infectivity for CD4-negative cells. AIDS Res Hum Retroviruses. 1995;11:547-553[Medline] [Order article via Infotrieve].
51.
Saifuddin M, Parker CJ, Peeples ME, et al.
Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.
J Exp Med.
1995;182:501-509 52. Guo MM, Hildreth JE. HIV acquires functional adhesion receptors from host cells. AIDS Res Hum Retroviruses. 1995;11:1007-1013[Medline] [Order article via Infotrieve]. 53. Hoxie JA, Fitzharris TP, Youngbar PR, et al. Nonrandom association of cellular antigens with HTLV-III virions. Hum Immunol. 1987;18:39-52[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  X. Huang, A. C. Wilber, L. Bao, D. Tuong, J. Tolar, P. J. Orchard, B. L. Levine, C. H. June, R. S. McIvor, B. R. Blazar, et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system Blood, January 15, 2006; 107(2): 483 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lai, E. S. Zimmerman, V. Planelles, and J. Chen Activation of the ATR Pathway by Human Immunodeficiency Virus Type 1 Vpr Involves Its Direct Binding to Chromatin In Vivo J. Virol., December 15, 2005; 79(24): 15443 - 15451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shibuya, J. Shirakawa, T. Kameyama, S.-i. Honda, S. Tahara-Hanaoka, A. Miyamoto, M. Onodera, T. Sumida, H. Nakauchi, H. Miyoshi, et al. CD226 (DNAM-1) Is Involved in Lymphocyte Function-associated Antigen 1 Costimulatory Signal for Naive T Cell Differentiation and Proliferation J. Exp. Med., December 15, 2003; 198(12): 1829 - 1839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bovia, P. Salmon, T. Matthes, K. Kvell, T. H. Nguyen, C. Werner-Favre, M. Barnet, M. Nagy, F. Leuba, J.-F. Arrighi, et al. Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors Blood, March 1, 2003; 101(5): 1727 - 1733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Ducrey-Rundquist, M. Guyader, and D. Trono Modalities of Interleukin-7-Induced Human Immunodeficiency Virus Permissiveness in Quiescent T Lymphocytes J. Virol., August 12, 2002; 76(18): 9103 - 9111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. VandenDriessche, L. Thorrez, L. Naldini, A. Follenzi, L. Moons, Z. Berneman, D. Collen, and M. K. L. Chuah Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo Blood, July 18, 2002; 100(3): 813 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Lenardo, S. B. Angleman, V. Bounkeua, J. Dimas, M. G. Duvall, M. B. Graubard, F. Hornung, M. C. Selkirk, C. K. Speirs, C. Trageser, et al. Cytopathic Killing of Peripheral Blood CD4+ T Lymphocytes by Human Immunodeficiency Virus Type 1 Appears Necrotic rather than Apoptotic and Does Not Require env J. Virol., April 16, 2002; 76(10): 5082 - 5093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, H. J. Chun, W. Wong, D. M. Spencer, and M. J. Lenardo Caspase-10 is an initiator caspase in death receptor signaling PNAS, November 20, 2001; 98(24): 13884 - 13888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Lewis, N. Chinnasamy, R. A. Morgan, and H. E. Varmus Development of an Avian Leukosis-Sarcoma Virus Subgroup A Pseudotyped Lentiviral Vector J. Virol., October 1, 2001; 75(19): 9339 - 9344. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-globin polyadenylation site
B,
and MIP1